» Articles » PMID: 38742057

The Role of Gut-lung Axis in COPD: Pathogenesis, Immune Response, and Prospective Treatment

Overview
Journal Heliyon
Specialty Social Sciences
Date 2024 May 14
PMID 38742057
Authors
Affiliations
Soon will be listed here.
Abstract

Chronic obstructive pulmonary disease (COPD) is a major cause of morbidity and healthcare burden worldwide. The progression of COPD is a combination of genetic predisposition and environmental factors, primarily cigarette smoking, and the underlying mechanisms are still unknown. Intestinal microecology impacts host immunity, metabolism, and resistance to pathogenic infections, which may be involved in pulmonary disease. Moreover, substantial interaction occurs between the intestinal and respiratory immune niches. After reviewing nearly 500 articles, we found the gut-lung axis plays an important role in the development of COPD. COPD patients often have dysbiosis of the intestinal microenvironment, which can affect host immunity through a series of mechanisms, exacerbating or protecting against COPD progression. This paper summarizes how the gut-lung axis influences COPD, including the alterations of intestinal microecology, the pathological mechanisms, and the involved immune responses. Finally, we summarize the latest research advances in COPD treatment from the perspective of regulating the gut-lung axis and intestinal immunity and evaluate the potential value of the gut-lung axis in improving COPD prognosis.

References
1.
Tweedle J, Deepe Jr G . Tumor Necrosis Factor Alpha Antagonism Reveals a Gut/Lung Axis That Amplifies Regulatory T Cells in a Pulmonary Fungal Infection. Infect Immun. 2018; 86(6). PMC: 5964519. DOI: 10.1128/IAI.00109-18. View

2.
Varraso R, Willett W, Camargo Jr C . Prospective study of dietary fiber and risk of chronic obstructive pulmonary disease among US women and men. Am J Epidemiol. 2010; 171(7):776-84. PMC: 2877480. DOI: 10.1093/aje/kwp455. View

3.
Raftery A, Tsantikos E, Harris N, Hibbs M . Links Between Inflammatory Bowel Disease and Chronic Obstructive Pulmonary Disease. Front Immunol. 2020; 11:2144. PMC: 7517908. DOI: 10.3389/fimmu.2020.02144. View

4.
Nici L, Mammen M, Charbek E, Alexander P, Au D, Boyd C . Pharmacologic Management of Chronic Obstructive Pulmonary Disease. An Official American Thoracic Society Clinical Practice Guideline. Am J Respir Crit Care Med. 2020; 201(9):e56-e69. PMC: 7193862. DOI: 10.1164/rccm.202003-0625ST. View

5.
Lai H, Lin T, Chen T, Kuo Y, Chang C, Wu T . Gut microbiota modulates COPD pathogenesis: role of anti-inflammatory lipopolysaccharide. Gut. 2021; 71(2):309-321. DOI: 10.1136/gutjnl-2020-322599. View